Michael Jantz, MD
Pulmonary Disease · Gainesville, FLNPI 1225077159
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (57.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 65.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $58,901 and has fallen 59.8% since, to $23,680 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $817.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$123K
- GE HealthCare$61K
- Pulmonx Corporation$2K
- AstraZeneca$572
- Galvanize Therapeutics, Inc$484
- GSK$463
- plus $1K from 9 others
Across 18 payments — averaging $7915.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$94K
- Concordia Laboratories Inc.$31K
- Boston Scientific$12K
- Pneumrx, Inc$6K
Across 4 payments — averaging $233.63 each. An ownership or investment interest held by the physician or an immediate family member.
- Spinal Surgical Strategies, Inc.$935
What the payments were for
- Consulting fees$56,68630%
- Speaking & faculty fees$4,4502%
- Travel & lodging$12,6337%
- Food & beverage$7,4004%
- Education$107,58257%
- Gifts$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 108 | $122,975 |
| GE HealthCare | 22 | $61,077 |
| Pulmonx Corporation | 26 | $2,229 |
| AstraZeneca | 31 | $572 |
| Galvanize Therapeutics, Inc | 2 | $484 |
| GSK | 23 | $463 |
| Pinnacle Biologics, Inc | 2 | $403 |
| Johnson & Johnson | 1 | $303 |
| ANI Pharmaceuticals, Inc. | 4 | $132 |
| Amgen | 4 | $85 |
| Insmed, Inc. | 3 | $72 |
| Lilly USA, LLC | 2 | $35 |
| Auris Health, Inc. | 1 | $32 |
| Boehringer Ingelheim | 1 | $18 |
| Veran Medical Technologies, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$119,425
- OEC$60,797
- DA VINCI SP$2,800
- Pulmonx Endobronchial Valve EBV$1,501
- Photofrin$403
- ALIYA SYSTEM$400
- Monarch Platform$303
How this compares
$188,888 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $159,100 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 184 | $148,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $51,791 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,379 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $11,394 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $8,281 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,817 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $6,015 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,385 |
| Ethambutol Hcl | 24 | $1,340 |
| Rifampin | 16 | $1,088 |
| Azithromycin | 34 | $966 |
| Pantoprazole Sodium | 46 | $641 |
| Rabeprazole Sodium | 14 | $640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $18 | $183,49550 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $572 | $156,774206 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $463 | $67,158111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Gainesville
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.